Best Income Stocks to Buy for June 10th

Written by Emily J. Thompson, Senior Investment Analyst

HMN-1.43%

NWFL-2.15%

Source: NASDAQ.COM

Updated: Jun 10 2025

0mins

Source: NASDAQ.COM

HMN

$42.73+Infinity%1D

Analyst Views on HMN

Wall Street analysts forecast HMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HMN is 48.00 USD with a low forecast of 48.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

0 Buy

1 Hold

0 Sell

Hold

Current: 43.350

Low

48.00

Averages

48.00

High

48.00

Current: 43.350

Low

48.00

Averages

48.00

High

48.00

BMO Capital

Michael Zaremski

Outperform

initiated

$48

2025-07-28

Reason

BMO Capital

Michael Zaremski

Price Target

$48

AI Analysis

2025-07-28

initiated

Outperform

Reason

BMO Capital analyst Michael Zaremski initiated coverage of Horace Mann with an Outperform rating and $48 price target. The company's captive-focused distribution differs from the majority of peer insurers who rely on 3rd party independent sales agents, the analyst tells investors in a research note. BMO adds that Horace Mann's strategy of selling mainly to schoolteachers via its captive salesforce is one that can bear meaningful fruit, so long as it executes on its current revamped sales strategy.

Piper Sandler

Neutral

maintain

$44 -> $45

2025-07-03

Reason

Piper Sandler

Price Target

$44 -> $45

2025-07-03

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Horace Mann to $45 from $44 and keeps a Neutral rating on the shares. The firm is reducing its EPS estimates in the space driven by continued fee and spread headwinds. This was confirmed by a rather challenging pre-announcement of variable investment income from MetLife (MET) in late June suggesting this swing factor for a large chunk of lifecoland got sequentially worse, which also - in Piper's opinion - pushes out the normalization factor towards 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HMN

Unlock Now

Raymond James

Strong Buy

maintain

$46 -> $49

2025-05-15

Reason

Raymond James

Price Target

$46 -> $49

2025-05-15

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Horace Mann to $49 from $46 and keeps a Strong Buy rating on the shares. The firm likes the company's strong distribution and sticky businesses, and tells investors in a research note that as Horace Mann executes on investor day targets, the stock should react favorably.

Keefe, Bruyette & Woods

Meyer Shields

Hold

Maintains

$44 → $45

2025-02-11

Reason

Keefe, Bruyette & Woods

Meyer Shields

Price Target

$44 → $45

2025-02-11

Maintains

Hold

Reason

Keefe Bruyette analyst Meyer Shields raised the firm's price target on Horace Mann to $45 from $44 and keeps a Market Perform rating on the shares. The shares' current valuation reasonably reflects its property and casualty margin improvement prospects, the analyst tells investors in a research note.

About HMN

Horace Mann Educators Corporation is a multiline financial services company focused on helping America’s educators and others who serve the community. The Company's Property & Casualty segment's primary insurance products include private passenger auto insurance, residential home insurance, and personal umbrella insurance. Its Life & Retirement segment markets 403 (b) tax-qualified fixed, fixed indexed and variable annuities; the Horace Mann Retirement Advantage open architecture platform for 403 (b) (7) and other defined contribution plans; traditional term and whole life insurance products and indexed universal life (IUL) products. Its Supplemental & Group Benefits segment offers employer-sponsored products, including accident, critical illness, limited-benefit fixed indemnity insurance, term life, short-term disability and long-term disability, and worksite direct products, including supplemental heart, supplemental cancer, supplemental disability and supplemental accident coverage.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.